daratumumab,talquetamab,teclistamab
genmab,janssen
['teclistamab']
#asco23 dual bispecific combination- teclistamab + talquetamb in triple class exposed, median prior line higher response rate than single agent 87%, 96% at rp2d, albeit less prior rx infection rate not significantly higher at current follow up pfs also higher at 20 m 
Assistant Professor @StanfordMed | Myeloma, Amyloidosis and Waldenstrom’s specialist | #CART #transplant | Proud 👩‍🎓: @MayoClinic @ClevelandClinic